中国药师
中國藥師
중국약사
CHINA PHARMACIST
2014年
12期
2082-2084
,共3页
王启盛%吕亚莉%陈传军%刘笑笑%杨彬
王啟盛%呂亞莉%陳傳軍%劉笑笑%楊彬
왕계성%려아리%진전군%류소소%양빈
盐酸羟考酮缓释片%起始治疗%中度癌痛%降阶梯
鹽痠羥攷酮緩釋片%起始治療%中度癌痛%降階梯
염산간고동완석편%기시치료%중도암통%강계제
Oxycodone hydrochloride prolonged-release tablets%Initial treatment%Moderate cancer pain%De-escalation
目的::比较盐酸羟考酮缓释片和盐酸曲马多缓释片治疗中度癌痛的疗效和安全性。方法:中度癌痛患者290例随机分为观察组148例与对照组142例。观察组口服盐酸羟考酮缓释片,对照组口服盐酸曲马多缓释片治疗,疗程2周。比较两组患者镇痛总有效率和不良反应发生情况。结果:观察组与对照组镇痛总有效率分别为92.6%和81.7%,差异有统计学意义(P<0.01);药品不良反应发生率分别为60.1%和57.0%,差异无统计学意义(P>0.05)。结论:盐酸羟考酮缓释片治疗中度癌痛患者优于盐酸曲马多缓释片。
目的::比較鹽痠羥攷酮緩釋片和鹽痠麯馬多緩釋片治療中度癌痛的療效和安全性。方法:中度癌痛患者290例隨機分為觀察組148例與對照組142例。觀察組口服鹽痠羥攷酮緩釋片,對照組口服鹽痠麯馬多緩釋片治療,療程2週。比較兩組患者鎮痛總有效率和不良反應髮生情況。結果:觀察組與對照組鎮痛總有效率分彆為92.6%和81.7%,差異有統計學意義(P<0.01);藥品不良反應髮生率分彆為60.1%和57.0%,差異無統計學意義(P>0.05)。結論:鹽痠羥攷酮緩釋片治療中度癌痛患者優于鹽痠麯馬多緩釋片。
목적::비교염산간고동완석편화염산곡마다완석편치료중도암통적료효화안전성。방법:중도암통환자290례수궤분위관찰조148례여대조조142례。관찰조구복염산간고동완석편,대조조구복염산곡마다완석편치료,료정2주。비교량조환자진통총유효솔화불량반응발생정황。결과:관찰조여대조조진통총유효솔분별위92.6%화81.7%,차이유통계학의의(P<0.01);약품불량반응발생솔분별위60.1%화57.0%,차이무통계학의의(P>0.05)。결론:염산간고동완석편치료중도암통환자우우염산곡마다완석편。
Objective: To investigate the efficacy and safety of oxycodone hydrochloride prolonged-release tablets and tramadol hydrochloride sustained-release tablets in the treatment of moderate cancer pain. Methods:Totally 290 cases of the patients with mod-erate pain were divided into the observation group with 148 cases and the control group with 142 cases. The observation group received oxycodone hydrochloride prolonged-release tablets, while the control group was given tramadol hydrochloride sustained-release tablets. The treatment course was 2 weeks, and the total efficiency and the incidence of adverse drug reactions( ADR) in the two groups were calculated and compared. Results:The total efficiency in the observation group and the control group was 92. 6% and 81. 7%, respec-tively, and the difference was statistically significant (P<0. 01). The incidence of ADR was 60. 1% and 57%, respectively with no significant difference (P>0.05). Conclusion: The effect of oxycodone hydrochloride prolonged-release tablets in the treatment of moderate cancer pain is better than that of tramadol hydrochloride sustained-release tablets.